History | Coexisting severe mental illness (psychosis) and substance misuse: assessment and management in healthcare settings | Guidance | NICE

Guidance
Skip Standards and indicators submenu
Quality standards
Our quality standards set out priority areas for quality improvement. They highlight areas with identified variation in current practice.
View our quality standards
How to use our quality standards
The timeline for developing quality standards
Help us develop quality standards
Selecting and prioritising quality standards topics
About quality standards
Indicators
Our indicators measure outcomes that reflect the quality of care, or processes linked by evidence to improved outcomes.
View list of indicators
Learn about the committee that develops indicators
About indicators
Skip Life sciences submenu
Life Sciences
We offer tailored support to industry during product development. Our expertise can help you build the evidence needed to achieve market access.
View life sciences
Get support from NICE
NICE Advice service
Trusted, unrivalled expertise.
Make an enquiry
Contact us to discuss your requirements.
Innovative Licensing and Access Pathway (ILAP)
Streamlining patient access to safe, financially sustainable and innovative medicines.
Learn how we evaluate technologies
Health technology evaluation and topic selection manuals
Updated manuals for methods, processes and topic selection.
Digital health technologies
Accelerating our efforts to deliver innovation to the health and care system.
Evidence standards framework
Using the best available evidence to develop recommendations that guide decisions in health, public health and social care.
Our guidance programmes
Ensuring new technologies are clinically effective and offer economic value.
Register your product
Non-pharmaceutical
HealthTech Connect is a clear and simple point of entry for health technologies to access support and national evaluation programmes.
Pharmaceutical
UK PharmaScan is a database of new medicines, indications and formulations in the pharmaceutical pipeline.
Find published and proposed evaluations
Diagnostics
Guidance on measurements and tests used to evaluate a patient's condition.
Medical technologies
Guidance on medical technologies put forward to NICE by manufacturers.
Technology appraisals
Guidance on new and existing medicines and treatments in the NHS.
Highly specialised technologies
Guidance on the use of highly specialised medicines and treatments.
British National Formulary (BNF)
British National Formulary for Children (BNFC)
Clinical Knowledge Summaries (CKS)
Skip About submenu
About
NICE helps practitioners and commissioners get the best care to patients, fast, while ensuring value for the taxpayer.
Explore about
Our programmes
Learn about the information we produce.
Guidance
Advice
Quality standards
Indicators
Digital health
Topic selection
Get involved
Understand how decisions are made:
Attend a committee meeting
Comment on draft guidance:
Guidance in consultation
Be part of a guidance committee:
Join a committee
Help develop our products:
Register as a stakeholder
Putting you at the heart of our work:
Public involvement
What we do
Social care
Life sciences
NICE international
Patient safety
Shared decision making
Into practice
Social care quick guides
Measuring the use of NICE guidance
Resource planner
View all Into practice
Who we are
The board
The NICE strategy 2021 to 2026
Corporate publications
View all Who we are
- Contact us
- Jobs

History

A list of downloadable documents created during development.

Review documents

Other information

Evidence update ^{PDF 320 KB} 01 December 2012

Background information

Psychosis with substance misuse: stakeholder list and how to register

Psychosis with substance misuse: list of stakeholders ^{PDF 46 KB} 10 February 2015

Psychosis with substance misuse: scoping workshop, consultation and final scope

Psychosis with substance misuse: scoping workshop, consultation and final scope
Psychosis with substance misuse: scope consultation information
Psychosis with substance misuse: scope comments table ^{PDF 229 KB} 28 May 2009
Psychosis with substance misuse: final scope ^{PDF 34 KB} 28 May 2009

Psychosis with substance misuse: guideline development and consultation

Psychosis with substance misuse: guideline development and consultation
Psychosis with substance misuse: guideline consultation information
Psychosis with substance misuse: guideline consultation - full guideline for consultation ^{PDF 2.39 MB} 10 August 2010
Psychosis with substance misuse: guideline consultation - full guideline appendices
Psychosis with substance misuse: guideline consultation - full guideline appendix 13 ^{PDF 360 KB} 10 August 2010
Psychosis with substance misuse: guideline consultation - full guideline appendix 14 ^{PDF 2.01 MB} 10 August 2010
Psychosis with substance misuse: guideline consultation - full guideline appendix 15 ^{PDF 334 KB} 10 August 2010
Psychosis with substance misuse: guideline consultation - full guideline appendix 16 ^{PDF 621 KB} 10 August 2010
Psychosis with substance misuse: guideline consultation - full guideline appendix 17 ^{PDF 103 KB} 09 August 2010
Psychosis with substance misuse: guideline consultation - full guideline appendix 18 ^{PDF 152 KB} 10 August 2010
Psychosis with substance misuse: guideline consultation - full guideline appendix 19 ^{PDF 157 KB} 09 August 2010
Psychosis with substance misuse: guideline consultation - NICE guideline for consultation ^{PDF 160 KB} 10 August 2010
Psychosis with substance misuse: list of stakeholders ^{PDF 46 KB} 10 February 2015
Psychosis with substance misuse: GDG membership list ^{PDF 14 KB} 28 May 2009
Psychosis with substance misuse: minutes for GDG meetings
Psychosis with substance misuse: GDG 1 - minutes ^{PDF 19 KB} 24 July 2009
Psychosis with substance misuse: GDG 2 - minutes ^{PDF 16 KB} 30 September 2009
Psychosis with substance misuse: GDG 3 - minutes ^{PDF 16 KB} 30 September 2009
Psychosis with substance misuse: GDG 4 - minutes ^{PDF 16 KB} 08 April 2010
Psychosis with substance misuse: GDG 5 - minutes ^{PDF 16 KB} 08 April 2010
Psychosis with substance misuse: GDG 6 - minutes ^{PDF 16 KB} 08 April 2010
Psychosis with substance misuse: GDG 7 - minutes ^{PDF 17 KB} 12 October 2010
Psychosis with substance misuse: GDG 8 and 9 - minutes ^{PDF 21 KB} 12 October 2010
Psychosis with substance misuse: equalities impact assessment (recommendations) ^{PDF 70 KB} 23 March 2011
Psychosis with substance misuse: final consultation comments with developer's responses table ^{PDF 636 KB} 23 March 2011

Psychosis with substance misuse: pre-publication check

Psychosis with substance misuse: pre-publication check information
Psychosis with substance misuse: pre-publication check - error reporting table ^{PDF 93 KB} 23 March 2011
Psychosis with substance misusue: pre-publication check - full guideline ^{PDF 2.88 MB} 07 January 2011
Psychosis with substance misusue: pre-publication check - full guideline appendices
Psychosis with substance misusue: pre-publication check - full guideline appendix 13, clinical study characteristics ^{PDF 355 KB} 07 January 2011
Psychosis with substance misusue: pre-publication check - full guideline appendix 14, forest plots ^{PDF 2.71 MB} 07 January 2011
Psychosis with substance misusue: pre-publication check - full guideline appendix 15, grade evidence profiles ^{PDF 371 KB} 07 January 2011
Psychosis with substance misusue: pre-publication check - full guideline appendix 16, methodology checklists ^{PDF 1.08 MB} 07 January 2011
Psychosis with substance misusue: pre-publication check - full guideline appendix 17, economic evidence profiles ^{PDF 101 KB} 07 January 2011
Psychosis with substance misusue: pre-publication check - full guideline appendix 18, economic methodoloogy checklist ^{PDF 143 KB} 07 January 2011
Psychosis with substance misusue: pre-publication check comments form ^{MSWord 55 KB} 07 January 2011
Psychosis with substance misusue: pre-publication check consultation tables with developer's responses ^{PDF 631 KB} 07 January 2011

Severe mental illness with problematic substance misuse: remit

Severe mental illness with problematic substance misuse: remit ^{PDF 11 KB} 27 July 2007